SURMOUNT-2

What is SURMOUNT-2?

Tirzepatide tested in adults who had both obesity and type 2 diabetes (Garvey et al., Lancet 2023).

Tirzepatide 15 mg gave −14.7% body weight at 72 weeks against −3.2% on placebo, with HbA1c reductions beyond most diabetes-specific GLP-1 trials. It is the evidence for Zepbound in people whose obesity comes with type 2 diabetes.

Related reading: SURMOUNT-2: Tirzepatide When You Also Have Diabetes

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where SURMOUNT-2 comes up on this site

On GLP Watchdog, SURMOUNT-2 comes up in 1 research article.

Other terms under trial

• SURMOUNT-5
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers